^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Glutamate inhibitor

    Related drugs:
    12d
    EGR1 Mediates Riluzole-Induced Apoptosis in Osteosarcoma via the Yap/p73-Bax Signaling Axis. (PubMed, bioRxiv)
    Together, these findings reveal a novel mechanism where Riluzole promotes apoptosis through upregulation of EGR1 , which then cooperates with YAP/p73 to activate Bax expression. These insights establish Riluzole as a promising therapeutic intervention for OS treatment through modulation of the EGR1 /Yap/p73/Bax signaling axis.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • EGR1 (Early Growth Response 1)
    |
    riluzole
    19d
    A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) (clinicaltrials.gov)
    P1, N=132, Completed, AbbVie | Active, not recruiting --> Completed
    Trial completion • Adverse events
    2ms
    Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Sep 2026
    Trial completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L11 (BCL2 Like 11)
    |
    sorafenib • riluzole
    4ms
    Effectiveness and safety of riluzole for the treatment of seizures in individuals with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). (ACTRN12625000845437)
    P2/3, N=5, Not yet recruiting, University of Melbourne
    New P2/3 trial
    |
    SCN8A (Sodium Voltage-Gated Channel Alpha Subunit 8)
    |
    riluzole
    4ms
    A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients (clinicaltrials.gov)
    P1/2, N=153, Recruiting, PLL TX AUSTRALIA PTY LTD | Not yet recruiting --> Recruiting
    Enrollment open
    5ms
    Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors (clinicaltrials.gov)
    P2, N=18, Completed, Jonsson Comprehensive Cancer Center | Recruiting --> Completed | Trial completion date: Nov 2026 --> Nov 2024 | Trial primary completion date: Nov 2025 --> Nov 2024
    Trial completion • Trial completion date • Trial primary completion date
    5ms
    A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) (clinicaltrials.gov)
    P1, N=132, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events
    5ms
    Design and synthesis of Riluzole-Ciprofloxacin hybrids as selective MST3 inhibitors for cancer treatment. (PubMed, Eur J Med Chem)
    The in vivo experiments demonstrated that LD-1 significantly suppressed tumor growth (TGI = 47.64 %) at a dosage of 40 mg/kg, coupled none obvious adverse reactions were observed. Collectively, LD-1, characterized by its novel structure, high potency, and selectivity as an MST3 inhibitor, showcases substantial potential for further investigation and therapeutic development.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CCNB1 (Cyclin B1)
    |
    riluzole
    5ms
    Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial (clinicaltrials.gov)
    P2, N=51, Recruiting, University of California, Irvine | N=34 --> 51 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    riluzole
    7ms
    Repurposing riluzole as an anti-osteosarcoma agent. (PubMed, Front Oncol)
    Additionally, riluzole suppresses the activity of matrix metalloprotease-2 (MMP2) in most of the osteosarcoma cell lines (but not the PDX cells). These results suggest that riluzole's inhibitory effects on osteosarcoma invasion may in part be attributable to the inhibition of MMP2 activity, and that riluzole is potentially an effective agent for inhibiting growth of primary and metastatic osteosarcomas with a wide range of genetic profiles.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    riluzole
    7ms
    Advantages and Disadvantages of Drug Combination Treatment: Riluzole, Metformin and Dexamethasone Effect on Glioblastoma Cell. (PubMed, Anticancer Res)
    Ril+Met co-treatment had a positive effect in terms of GBM cell death, decreased expression of genes involved in glucose metabolism and stemness, and reduced MMP2 activation. Disadvantage of Ril+Met treatment was increased cell migration. Taken together, these drug combinations may also allow the reduction of the concentration of Dex to minimize its side effects.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    dexamethasone • metformin • riluzole
    8ms
    RILUZOX-01: Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy. (clinicaltrials.gov)
    P2, N=80, Suspended, UNICANCER | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    oxaliplatin • riluzole